Compare LRE & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LRE | PMVP |
|---|---|---|
| Founded | 2001 | 2013 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2M | 79.5M |
| IPO Year | 2022 | 2020 |
| Metric | LRE | PMVP |
|---|---|---|
| Price | $1.35 | $1.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 23.9K | ★ 839.1K |
| Earning Date | 07-30-2015 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $0.82 |
| 52 Week High | $2.86 | $1.88 |
| Indicator | LRE | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 48.24 | 52.99 |
| Support Level | $1.34 | $1.32 |
| Resistance Level | $1.43 | $1.48 |
| Average True Range (ATR) | 0.09 | 0.09 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 16.84 | 1.36 |
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa Prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment units to individual customers in Japan and Dallas, Texas. Its revenue is predominantly generated from developing and selling single-family homes and condominiums, hotel operations, and residential leasing. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.